As for the future of the site, Silverman writes: "Yes, there were discussions to continue with Pharmalot – the Ledger, particularly [Jim Willse, editor of The Star-Ledger], recognizes the potential for the site and I thoroughly enjoy the work. The long hours and intense routine may be grueling, but Pharmalot has been an extremely challenging and satisfying preoccupation. In the end, though, we were unable to find a path forward."
Pharmalot reported 11,000 unique daily visitors and 330,000 monthly page views on a 30-day rolling basis last month, said Silverman by blog. It regularly covered companies like Pfizer, AstraZeneca, Merck, and GlaxoSmithKline. The Star-Ledger said in October that it would cut 40% of its newsroom staff by the end of the year.
Have you registered with us yet?
Register now to enjoy more articles and free email bulletinsRegister